Alicia Algeciras-Schimnich, Joshua A. Bornhorst, Daniel J. Figdore, Ramiro Eduardo Rea Reyes, Susan Ashrafzadeh-Kian, Rachel Wilson, Brian J. Burkett, D H Johnson, Hugo Botha, Stuart J. McCarter, Gregory S. Day, Jonathan Graff-Radford, Vijay K. Ramanan, Clifford R. Jack, Sterling C. Johnson, Henrik Zetterberg, Ronald C. Petersen
This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.